ID   BT474-LR
AC   CVCL_VL01
SY   BT474/LR; BT474 LR
DR   BTO; BTO_0006065
DR   cancercelllines; CVCL_VL01
DR   Wikidata; Q93432846
RX   PubMed=25590338;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene fusion; HGNC; HGNC:24618; AHCTF1 + HGNC; HGNC:736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:16173; DOK5 + HGNC; HGNC:17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:13178; IKZF3 + HGNC; HGNC:12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:16651; MRPL45 + HGNC; HGNC:16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7609; MYO9B + HGNC; HGNC:9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0179 ! BT-474
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 10-04-25; Version: 10
//
RX   PubMed=25590338; DOI=10.4161/15384101.2014.994966; PMCID=PMC4614407;
RA   Canfield K., Li J.-Q., Wilkins O.M., Morrison M.M., Ung M., Wells W.,
RA   Williams C.R., Liby K.T., Vullhorst D., Buonanno A., Hu H.-Z., Schiff R.,
RA   Cook R.S., Kurokawa M.;
RT   "Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2
RT   inhibitors in breast cancer cells.";
RL   Cell Cycle 14:648-655(2015).
//